Year: 2025
Type: article
Abstract: In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual disease (MRD), has rapidly shifted from a theoretical indicator to a powerful, practice-changing tool. At the forefront of this shift is multiple myeloma (MM), where MRD has emerged as a highly sensitive measure of treatment response and a compelling surrogate marker for long-term outcomes.
Source: EMJ Hematology
Author: Helena Bradbury
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4410547397